Sustained-release dosage forms of ruxolitinib
US11337927B2 · kind B2 · utility
10Cited by
120References
34Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 16, 2020 |
| Grant date | May 24, 2022 |
| Priority date | — |
| Expiry date | Nov 17, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.